• Actinomycin D in Vascular mRNA Stability Research

  2026-09-28

  Actinomycin D (ActD) can help distinguish changes in mRNA production from changes in transcript decay. This article connects transcriptional inhibition to a recent NF90–FBXW7–AGER1 study of diabetic vascular calcification and explains how to interpret the assay without mistaking a broad inhibitor for a pathway-specific probe.

• Cyclic di-GMP, HipH, and Biofilm Persistence

  2026-09-27

  A 2024 eLife study identifies cyclic di-GMP as a small-molecule antitoxin that restrains the genotoxic toxin HipH during early biofilm development. Its findings connect cell adhesion, DNA damage, genome stability, and antibiotic persistence, expanding explanations of biofilm resilience beyond conditions in mature biofilms.

• Autophagy–Metastasis Signature in Colorectal Cancer

  2026-09-26

  Bai et al. developed and externally validated a six-gene colorectal cancer risk signature integrating autophagy- and liver metastasis-associated expression, then used bulk and single-cell analyses to examine its links with immune states. The results suggest that high-risk tumors have an immunosuppressive profile and potentially weaker predicted immunotherapy response, but prospective and functional studies are needed before clinical use.

• EGFR/HER2 Inhibition: From Mechanism to Translation

  2026-09-25

  A translational framework for using BMS 599626 dihydrochloride to investigate EGFR and ErbB2 signaling. The article connects receptor-level pharmacology with rigorous assay design, context-aware interpretation, and lessons from machine-learning-enabled senolytic discovery—without conflating distinct mechanisms or evidence bases.

• ARCA Cy3 EGFP mRNA (5-moUTP): Uses & Limits

  2026-09-25

  ARCA Cy3 EGFP mRNA (5-moUTP) combines a Cy3-labeled RNA delivery readout with an EGFP protein-expression readout. This 5-methoxyuridine modified mRNA is a research tool for tracking delivery and evaluating expression, not a standalone measure of endosomal escape or a guaranteed transfection protocol.

• Nitrocefin for β-Lactamase Activity Assays

  2026-09-24

  Use Nitrocefin for a rapid, visible readout of β-lactamase activity, then pair that screen with antibiotic-specific assays to characterize resistance mechanisms more fully. A practical workflow for purified enzymes and bacterial lysates includes assay controls, starting conditions, and troubleshooting for metallo-β-lactamases such as GOB-38.

• Firefly Luciferase mRNA: A Practical Assay Guide

  2026-09-24

  Use modified Firefly Luciferase mRNA as a bright, non-integrating reporter to check delivery and expression before committing to a complex experiment. This guide turns the product’s handling details and a recent mRNA-delivery study into a practical workflow—with clear limits on what luminescence can and cannot tell you.

• High Yield T7 Biotin16 RNA Labeling Kit: Research Guide

  2026-09-23

  The High Yield T7 Biotin16 RNA Labeling Kit (K1082) is a T7 RNA-labeling product, but the supplied product dossier does not specify its formulation or reaction settings. A 2025 METTL14–SMN study provides relevant RNA-biology context; it did not test K1082 or establish the kit as an m6A assay.

• Plerixafor (AMD3100) Experimental Workflows

  2026-09-23

  Plerixafor (AMD3100) provides a practical CXCR4/CXCL12 blockade strategy for migration assays, cancer biology, stem cell mobilization, and immune-cell trafficking studies. This guide connects benchmark pharmacology with reproducible workflows, formulation guidance, comparative testing, and troubleshooting.

• Thioguanine Workflows for Cancer and EV71 Studies

  2026-09-22

  Thioguanine and 6-thioguanine support distinct but connected workflows for cancer-cell response, EV71 virus inhibition, and mechanistic epigenetic studies. This guide translates reported potency into practical dose–response design, orthogonal readouts, solvent controls, and troubleshooting strategies without confusing exploratory bench evidence with clinical validation.

• Actinomycin D as a Translational Stress Probe

  2026-09-22

  Actinomycin D is more than a cytotoxic transcriptional inhibitor: used with appropriate controls, it can help translational researchers distinguish altered RNA synthesis from RNA stability in disease models. This article connects ActD mechanism with the DNMT3A–STAT5B–MBP axis identified in Parkinson’s disease oligodendrocytes and outlines a practical, limitation-aware validation strategy.

• Chuanxiong Cortex vs Pith in Coronary Heart Disease

  2026-09-21

  This study distinguishes the volatile chemical profiles and predicted pharmacological mechanisms of Chuanxiong rhizome cortex and pith in coronary heart disease research. By integrating SPME-GC×GC-MS, network pharmacology, pathway analysis, and molecular docking, it provides a tissue-resolved framework for evaluating a traditionally composite herbal drug.

• Dextran sulfate sodium salt for DSS colitis models

  2026-09-21

  Dextran sulfate sodium salt, DSS (MW 35000-45000), provides a controllable epithelial injury platform for acute colitis, mucosal repair, and therapeutic screening. This guide connects practical model design with GPR35–KLF5 repair biology while addressing concentration, solution handling, variability, and interpretation.

• Forskolin, cAMP, and Neuronal Calcium Assays

  2026-09-20

  Forskolin is an adenylate cyclase activator that can turn cAMP signaling into a mechanistic assay variable. This article explains how the compound helped reveal glucocorticoid control of Kv2.1–CaV1.2 calcium signaling and translates that logic into rigorous experimental design.

• Talabostat mesylate: Assays for FAP and CARD8

  2026-09-19

  Talabostat mesylate, also called PT-100 or Val-boroPro, supports distinct workflows for FAP biology, DPP4 inhibition in cancer research, and CARD8-linked pyroptosis. This guide combines tumor-cell assays with resting-versus-activated T-cell comparisons and practical controls for interpretable results.

551 records 3/37 page Previous Next 12345 下5页 Last page